+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin



Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin



Journal of Infectious Diseases 198(6): 808-812



To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1. Forty-two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon alpha-2a (n = 20) or alpha-2b (n = 22) combined with oral ribavirin for 48 weeks. There was no difference between genotypes 1 and 6 in the rates of early virological response (76% vs. 81%; P > .05) and end-of-treatment response (71% vs. 81%; ). Patients infected with genotype 6 had a higher rate of sustained virological response (SVR) than did patients infected with genotype 1 (86% vs. 52%; P = .019). The overall adverse-effects profile was similar in both genotype groups. There was no significant difference in the rate of SVR between patients receiving pegylated interferon alpha-2a and those receiving alpha-2b. Multivariate analysis showed that genotype was the only significant factor associated with SVR (P = .039). Treatment with pegylated interferon and ribavirin for 48 weeks resulted in a significantly higher rate of SVR in patients infected with genotype 6 than in those infected with genotype 1. Further studies are required to determine whether lower dosages and 24 weeks of therapy may be sufficient for the treatment of genotype 6 infection.

(PDF emailed within 0-6 h: $19.90)

Accession: 052079501

Download citation: RISBibTeXText

PMID: 18657036

DOI: 10.1086/591252


Related references

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. Journal of Medical Virology 77(1): 66-69, 2005

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384(9956): 1756-1765, 2015

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clinical Infectious Diseases 62(1): 32-36, 2016

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52(3): 822-832, 2010

A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection. Nihon Rinsho. Japanese Journal of Clinical Medicine 73(2): 266-272, 2015

A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection. Nihon Rinsho. Japanese Journal of Clinical Medicine 73 Suppl 9: 248-253, 2016

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis. Bmj Open Gastroenterology 2(1): E000057, 2015

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Annals of Hepatology 11(2): 186-193, 2012

FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology 147(6): 1196-1200, 2015

Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. Hepatology Research 47(3): E142-E151, 2016

Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology 45(2): 250-255, 2010

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. Bmc Infectious Diseases 17(1): 420, 2017

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. Journal of Infectious Diseases 202(8): 1185-1191, 2010

The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Archives of Virology 160(4): 1043-1054, 2015